Evidence map›Paper›PMID 34926045›Full record

ArticleCureus2021

Surviving Over a Decade With Glioblastoma: A Clinical Course Characterized by Multiple Recurrences, Numerous Salvage Treatments, and Novel Use of Cesium-131 Tiles.

Shahil Mehta, April K Vassantachart, Croix C Fossum, Wensha Yang, Zhilei L Shen, Ki-Eun Chang, Jason C Ye, Thomas C Chen, Eric L Chang

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. GammaTileJournal of neuro-oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shahil MehtaDepartment of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
April K VassantachartDepartment of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
Croix C FossumDepartment of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
Wensha YangDepartment of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
Zhilei L ShenDepartment of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
Ki-Eun ChangDepartment of Neurosurgery, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
Jason C YeDepartment of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
Thomas C ChenDepartment of Neurosurgery, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
Eric L ChangDepartment of Radiation Oncology, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
University of Southern California · US

Funding

Advanced prediction of GBM recurrence (TIME) for personalized radiotherapyR21CA267139 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YANG, WENSHA · 2022 to 2024
$411k
NCI NIH HHS R21 CA267139
6 · The paper itself

Abstract

The prognosis for patients diagnosed with recurrent glioblastoma (GBM) remains poor, with no clear standard of care regarding salvage therapy. Common approaches include chemotherapy, re-resection, tumor treating fields, and reirradiation. However, most studies have shown these to have limited benefits. Reirradiation is particularly difficult due to concern for increased risk of toxicity to surrounding normal brain tissue. A novel intracranial brachytherapy system called GammaTile® (GT Medical Technologies, Tempe, Arizona) involves the placement of Cesium-131 radioactive tiles in the tumor cavity following maximal safe resection. This allows for a highly conformal dose distribution with rapid fall-off to minimize overlap with prior radiation fields and for the application of radiation directly to the high-risk tumor bed. This case report highlights a patient with GBM who survived 11.5 years through multiple recurrences and discusses the many salvage treatments he received, including bevacizumab, irinotecan, and stereotactic radiosurgery (SRS). This case exemplifies that aggressive systemic and local therapies can work well in select patients allowing for long-term survival with a good quality of life. Further efforts should be made to identify which patients may benefit from these therapies. The case study additionally reports on the use of GammaTile therapy. Due to prior external beam radiation therapy and SRS to the treatment site, further external beam radiation options were limited, and the patient was offered GammaTile as local therapy. Although it did not provide a survival benefit in this case due to progressive disease outside of the field of treatment, GammaTile serves as a valuable option in providing local therapy to patients who can no longer receive further radiation. It should be used with careful consideration in lesions characterized by aggressive local invasion.

Indexed as

cs 131gammatileglioblastomaintracranial brachytherapyradiation oncologystereotactic radio surgery (srs)surgically targeted radiation therapy

Identifiers

PMID34926045
PMCPMC8671070
OpenAlexW3213032521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.